trial|CCR:“復旦分型”再出擊!邵志敏團隊使用三聯免疫治療方案,刷新TNBC一線最佳療效( 三 )


4.Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436-446. doi:10.1016/S1470-2045(15)70064-1
5.Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018;29(8):1741-1747. doi:10.1093/annonc/mdy209